Medical device CE marking

MDCG 2022-5 Rev. 1 published on (MDR) borderline products: medical devices and medicinal products

2024-10

On October 29, 2024 the MDCG published Revision 1 of MDCG 2022-5: Guidance on borderline between medical devices and medicinal products under Regulation (EU) 2017/745 on medical devices.

The document starts with the general discussion of the borderline between medical devices and medicinal products, including relevant definitions and examples. Separate chapters are dedicated to herbal products, substance-based devices and medical device and medicinal product combinations.

The document can be downloaded in our library

Source: European Commission

MDCG issued 2024-13 on regulatory status of EtO

2024-10

The regulatory status of ethylene oxide (EtO) for the sterilisation of single-use medical devices during the manufacturing process has been discussed in relation to the Review Programme under Regulation (EU) 528/2012 on biocidal products (BPR).

Ethylene oxide (EtO) is used to sterilise a wide range of medical products, such as medical devices, in vitro diagnostic medical devices (IVDs) and medicinal products, as well as products combining them. Sterilisation of products that are placed on the market in sterile condition is part of the manufacturing process and is usually carried out in large industrial units either by the manufacturers themselves or by external sterilisation service providers.

On a much smaller scale, EtO is also provided in cartridges for sterilisation of reusable medical devices, mainly in health institutions for use of such devices. Those EtO-containing cartridges, which are used for the supply of EtO to specific EtO sterilisers, are generally CE marked in accordance with the previous Directive 93/42/EEC or the current Regulation (EU) 2017/745 on medical devices (the ‘MDR’).

The document can be downloaded in our library

Source: European Commission

MDCG 2021-25 Rev.1 report issued on transitional provisions

2024-10

The MDCG ad hoc task-force on transitional provisions (‘legacy devices’ and devices placed on the market prior to 26 May 2021 in accordance with Directives 90/385/EEC or 93/42/EEC) has issued Revision 1 of the MDCG 2021-25 report, which has been endorsed as an MDCG guidance.

The document can be downloaded in our library

Source: European Commission

 

Current status MDR / IVDR Notified Bodies

2024-10

At the moment there are 50 notified bodies designated to perform audits according the MDR:

The current status of NBs under the IVDR is 13:

Source: NANDO database

Call to medical device manufacturers: implement an effective PMS system

2024-10

Original communication:

Manufacturers should pay more attention to the continuous monitoring of the safety of medical devices

It is important that medical device manufacturers continuously monitor the quality and safety of their products. European regulations apply to the implementation of this surveillance, also called Post-Market Surveillance (PMS). The Dutch inspection (IGJ) visits to 13 manufacturers showed that manufacturers do not comply with this or do not comply sufficiently. Most manufacturers seem to give too little priority to PMS. The inspectorate calls on manufacturers to change this. It is about patient safety, but also about the improvement and further development of medical devices.

Post-Market Surveillance contributes to the safe use of medical devices
Medical devices include diagnostic tests, medical software, IV poles or treatment tables. PMS consists of activities that a manufacturer must perform to monitor the performance and safety of the device. Examples include conducting (user) research into the product and analyzing incidents and complaints.

It is important that manufacturers continually assess whether the benefits of their product outweigh the risks. If necessary, they must make adjustments or improvement measures. Regular reporting of PMS results is also mandatory. This applies from the moment a product is placed on the market. The purpose of PMS is that the manufacturer always has the correct information about the medical device and thus improves its safe use.

None of the 13 manufacturers met the PMS requirements
In 2023 and 2024, the Dutch inspectorate visited 13 manufacturers of various medical devices, software applications and in-vitro diagnostics (tools for testing human body material, such as a pregnancy test). None of the 13 fully met the European requirements for PMS. The IGJ often saw, among other things, that a PMS plan is missing, knowledge is limited or that the PMS is not focused on the medical device in question. The manufacturers themselves often indicate that they find the regulations complex. The IGJ has asked the manufacturers to resolve the shortcomings.

IGJ call to manufacturers: work on PMS
Following these inspections, the IGJ encourages all manufacturers of medical devices to implement PMS and to give it priority. This can be done, among other things, by clearly assigning responsibility for PMS within the organization and making it part of the entire quality system.

In the coming period, the IGJ will continue to visit manufacturers of medical devices to check whether they meet the PMS requirements. In addition, the IGJ continues to draw attention to the importance of quality and safety control at both national and international levels.

The publication can be downloaded in our library

Source: Call to medical device manufacturers: implement an effective PMS system | Publication | Health and Youth Care Inspectorate (igj.nl)

 

MDCG issued 2024-11 on qualification of in vitro diagnostic medical devices

2024-10

The purpose of this guidance document is to clarify what products fall in scope of Regulation 2017/746 on in vitro diagnostic medical devices (IVDR) – also referred to as ‘qualification’ as an in vitro diagnostic medical device (IVD) or an accessory to an IVD. In order to be qualified as an IVD or an accessory to an IVD, the product must fulfil the definition in Art 2(2) or Art 2(4) of the IVDR respectively. The qualification depends on the intended purpose as described by the manufacturer.

The document can be downloaded in our library

Source: European Commission

Updated Code of Conduct for Notified Bodies

2024-09

The European Association of Medical Devices of Notified Bodies (Team NB) has issued version 5.0 of the Code of Conduct for Notified Bodies.

The Code of Conduct is a voluntary code to improve harmonized implementation of the European directives, creating a more level playing field for manufacturers.

The latest Code of Conduct you may download in our library

Source: http://www.team-nb.org

Revision 2 of MDR and IVDR language requirements for manufacturers published

2024-09

The Commission and Member States have created a revision 2 of the MDR and IVDR tables.

These tables aim to help manufacturers of medical devices and in vitro diagnostic medical devices, particularly small and medium-sized ones, understand the language requirements for the information and instructions that accompany a device in a specific country. The tables provide an overview of the language requirements for each Member State.

Graphic User Interface (GUI)
The last column of the tables includes the language requirements about the graphic user interface (GUI) (e.g., apps). There is no specific article foreseen in MDR/IVDR, but some countries have their own national legislation and rules about GUIs.

The documents can be downloaded in our library: MDR / IVDR

Source: European Commission

All documents related to the MDR and IVDR amending Regulations

2024-07

Please find below an overview of all documents related to the MDR and IVDR amendments, Regulations (EU) 2023/607 and (EU) 2024-1860.

You can press on the link to download the document in our library.

MDR/IVDR amending Regulations:

MDD/MDR related documents:

IVDD/IVDR related documents: